{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T13:18:45Z","timestamp":1775308725398,"version":"3.50.1"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SARS-CoV-2 infected a large fraction of humans in the past 2 years. The clinical presentation of acute infection varies greatly between individuals, ranging from asymptomatic or mild to life-threatening COVID-19 pneumonia with multi-organ complications. Demographic and comorbid factors explain part of this variability, yet it became clear early in the pandemic that human genetic variation also plays a role in the stark differences observed amongst SARS-CoV-2 infected individuals. Using tools and approaches successfully developed for human genomic studies in the previous decade, large international collaborations embarked in the exploration of the genetic determinants of multiple outcomes of SARS-CoV-2 infection, with a special emphasis on disease severity. Genome-wide association studies identified multiple common genetic variants associated with COVID-19 pneumonia, most of which in regions encoding genes with known or suspected immune function. However, the downstream, functional work required to understand the precise causal variants at each locus has only begun. The interrogation of rare genetic variants using targeted, exome, or genome sequencing approaches has shown that defects in genes involved in type I interferon response explain some of the most severe cases. By highlighting genes and pathways involved in SARS-CoV-2 pathogenesis and host-virus interactions, human genomic studies not only revealed novel preventive and therapeutic targets, but also paved the way for more individualized disease management.<\/jats:p>","DOI":"10.1038\/s41431-022-01136-4","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T01:02:37Z","timestamp":1656550957000},"page":"908-914","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Host genomics of SARS-CoV-2 infection"],"prefix":"10.1038","volume":"30","author":[{"given":"Claire","family":"Redin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Thorball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-939X","authenticated-orcid":false,"given":"Jacques","family":"Fellay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"1136_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141\u201354.","journal-title":"Nat Rev Microbiol"},{"key":"1136_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","volume":"590","author":"M O\u2019Driscoll","year":"2021","unstructured":"O\u2019Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021;590:140\u20135.","journal-title":"Nature"},{"key":"1136_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/S0140-6736(21)02867-1","volume":"399","author":"COVID-19 Forecasting Team.","year":"2022","unstructured":"COVID-19 Forecasting Team. Variation in the COVID-19 infection\u2013fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis. Lancet. 2022;399:1469\u201388.","journal-title":"Lancet"},{"key":"1136_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","volume":"27","author":"P Brodin","year":"2021","unstructured":"Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27:28\u201333.","journal-title":"Nat Med"},{"key":"1136_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41577-020-0373-7","volume":"20","author":"SY Zhang","year":"2020","unstructured":"Zhang SY, Zhang Q, Casanova JL, Su HC. Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? Nat Rev Immunol. 2020;20:455\u20136.","journal-title":"Nat Rev Immunol"},{"key":"1136_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41576-020-00297-6","volume":"22","author":"AJ Kwok","year":"2021","unstructured":"Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat Rev Genet. 2021;22:137\u201353.","journal-title":"Nat Rev Genet"},{"key":"1136_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl J Med. 2020;382:727\u201333.","journal-title":"N. Engl J Med"},{"key":"1136_CR8","doi-asserted-by":"crossref","unstructured":"The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020;28:715\u20138.","DOI":"10.1038\/s41431-020-0636-6"},{"key":"1136_CR9","unstructured":"The Severe Covid-19 GWAS Group. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. New Engl J Med]. 2020; Available from: https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2020283."},{"key":"1136_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2021","unstructured":"Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, et al. Genetic mechanisms of critical illness in COVID-19. Nature 2021;591:92\u20138.","journal-title":"Nature"},{"key":"1136_CR11","unstructured":"COVID-19 Host Genetics Initiative and others. Mapping the human genetic architecture of COVID-19. 2021;600:472\u20137."},{"key":"1136_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41588-022-01042-x","volume":"54","author":"GHL Roberts","year":"2022","unstructured":"Roberts GHL, Partha R, Rhead B, Knight SC, Park DS, Coignet MV, et al. Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects. Nat Genet. 2022;54:374\u201381.","journal-title":"Nat Genet"},{"key":"1136_CR13","doi-asserted-by":"crossref","unstructured":"Horowitz JE, Kosmicki JA, Damask A, Sharma D, Roberts GHL, Justice AE, et al. Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease. Nat Genet. 2022;54:382-92.","DOI":"10.1038\/s41588-021-01006-7"},{"key":"1136_CR14","unstructured":"Kousathanas A, Pairo-Castineira E, Rawlik K, Stuckey A, Odhams CA, Walker S, et al. Whole genome sequencing reveals host factors underlying critical Covid-19. Nature. 2022;1\u201310."},{"key":"1136_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-021-00318-6","volume":"7","author":"Y Li","year":"2021","unstructured":"Li Y, Ke Y, Xia X, Wang Y, Cheng F, Liu X, et al. Genome-wide association study of COVID-19 severity among the Chinese population. Cell Disco. 2021;7:1\u201316.","journal-title":"Cell Disco"},{"key":"1136_CR16","doi-asserted-by":"publisher","first-page":"110020","DOI":"10.1016\/j.celrep.2021.110020","volume":"37","author":"M D\u2019Antonio","year":"2021","unstructured":"D\u2019Antonio M, Nguyen JP, Arthur TD, Matsui H, D\u2019Antonio-Chronowska A, Frazer KA. SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues. Cell Rep. 2021;37:110020.","journal-title":"Cell Rep"},{"key":"1136_CR17","doi-asserted-by":"crossref","unstructured":"Nakanishi T, Pigazzini S, Degenhardt F, Cordioli M, Butler-Laporte G, Maya-Miles D, et al. Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. J Clin Invest. 2021; Available from: https:\/\/www.jci.org\/articles\/view\/152386.","DOI":"10.1101\/2021.03.07.21252875"},{"key":"1136_CR18","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41586-020-2818-3","volume":"587","author":"H Zeberg","year":"2020","unstructured":"Zeberg H, P\u00e4\u00e4bo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature 2020;587:610\u20132.","journal-title":"Nature"},{"key":"1136_CR19","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/s41588-021-00955-3","volume":"53","author":"DJ Downes","year":"2021","unstructured":"Downes DJ, Cross AR, Hua P, Roberts N, Schwessinger R, Cutler AJ, et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus. Nat Genet. 2021;53:1606\u201315.","journal-title":"Nat Genet"},{"key":"1136_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00519-1","volume":"6","author":"Y Yao","year":"2021","unstructured":"Yao Y, Ye F, Li K, Xu P, Tan W, Feng Q, et al. Genome and epigenome editing identify CCR9 and SLC6A20 as target genes at the 3p21.31 locus associated with severe COVID-19. Sig Transduct Target Ther. 2021;6:1\u20133.","journal-title":"Sig Transduct Target Ther"},{"key":"1136_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02454-4","volume":"22","author":"S Kasela","year":"2021","unstructured":"Kasela S, Daniloski Z, Bollepalli S, Jordan TX, tenOever BR, Sanjana NE, et al. Integrative approach identifies SLC6A20 and CXCR6 as putative causal genes for the COVID-19 GWAS signal in the 3p21.31 locus. Genome Biol. 2021;22:242.","journal-title":"Genome Biol"},{"key":"1136_CR22","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1128\/CMR.00109-14","volume":"28","author":"L Cooling","year":"2015","unstructured":"Cooling L. Blood groups in infection and host susceptibility. Clin Microbiol Rev. 2015;28:801\u201370.","journal-title":"Clin Microbiol Rev"},{"key":"1136_CR23","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1001\/jama.293.12.1450-c","volume":"293","author":"Y Cheng","year":"2005","unstructured":"Cheng Y, Cheng G, Chui CH, Lau FY, Chan PKS, Ng MHL, et al. ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 2005;293:1447\u201351.","journal-title":"JAMA"},{"key":"1136_CR24","doi-asserted-by":"publisher","first-page":"e0239508","DOI":"10.1371\/journal.pone.0239508","volume":"15","author":"D Golinelli","year":"2020","unstructured":"Golinelli D, Boetto E, Maietti E, Fantini MP. The association between ABO blood group and SARS-CoV-2 infection: A meta-analysis. PLOS ONE. 2020;15:e0239508.","journal-title":"PLOS ONE"},{"key":"1136_CR25","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41588-021-00854-7","volume":"53","author":"JF Shelton","year":"2021","unstructured":"Shelton JF, Shastri AJ, Ye C, Weldon CH, Filshtein-Sonmez T, Coker D, et al. Trans-ancestry analysis reveals genetic and nongenetic associations with COVID-19 susceptibility and severity. Nat Genet. 2021;53:801\u20138.","journal-title":"Nat Genet"},{"key":"1136_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/trf.16748","volume":"62","author":"M Guti\u00e9rrez-Valencia","year":"2022","unstructured":"Guti\u00e9rrez-Valencia M, Leache L, Librero J, Jeric\u00f3 C, Enguita Germ\u00e1n M, Garc\u00eda-Erce JA. ABO blood group and risk of COVID-19 infection and complications: A systematic review and meta-analysis. Transfusion 2022;62:493\u2013505.","journal-title":"Transfusion"},{"key":"1136_CR27","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020;367:1444\u20138.","journal-title":"Science"},{"key":"1136_CR28","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.1016\/S2665-9913(20)30345-3","volume":"2","author":"J Bovijn","year":"2020","unstructured":"Bovijn J, Lindgren CM, Holmes MV. Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19. Lancet Rheumatol 2020;2:e658\u20139.","journal-title":"Lancet Rheumatol"},{"key":"1136_CR29","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","volume":"397","author":"O Abani","year":"2021","unstructured":"Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637\u201345.","journal-title":"Lancet"},{"key":"1136_CR30","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523\u201334.","journal-title":"Nat Rev Microbiol"},{"key":"1136_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","volume":"20","author":"D Acharya","year":"2020","unstructured":"Acharya D, Liu GQ, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20:397\u20138.","journal-title":"Nat Rev Immunol"},{"key":"1136_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020;369:718\u2212+.","journal-title":"Science"},{"key":"1136_CR33","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1056\/NEJMcp2009575","volume":"383","author":"DA Berlin","year":"2020","unstructured":"Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N. Engl J Med. 2020;383:2451\u201360.","journal-title":"N. Engl J Med"},{"key":"1136_CR34","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"W Guan","year":"2020","unstructured":"Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of Coronavirus disease 2019 in China. N. Engl J Med 2020;382:1708\u201320.","journal-title":"N. Engl J Med"},{"key":"1136_CR35","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.cell.2020.05.016","volume":"181","author":"JL Casanova","year":"2020","unstructured":"Casanova JL, Su HC, Abel L, Aiuti A, Almuhsen S, Arias AA, et al. A global effort to define the human genetics of protective immunity to SARS-CoV-2 infection. Cell 2020;181:1194\u20139.","journal-title":"Cell"},{"key":"1136_CR36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1001\/jama.2020.13719","volume":"324","author":"CI van der Made","year":"2020","unstructured":"van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of genetic variants among young men with severe COVID-19. JAMA 2020;324:663\u201373.","journal-title":"JAMA"},{"key":"1136_CR37","doi-asserted-by":"crossref","unstructured":"Asano T, Boisson B, Onodi F, Matuozzo D, Moncada-Velez M, Renkilaraj MRLM, et al. X-linked recessive TLR7 deficiency in similar to 1% of men under 60 years old with life-threatening COVID-19. Sci Immunol. 2021;6:eabl4348.","DOI":"10.1126\/sciimmunol.abl4348"},{"key":"1136_CR38","unstructured":"Fallerini C, Daga S, Mantovani S, Benetti E, Picchiotti N, Francisci D, et al. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. Elife. 2021;10:e67569."},{"key":"1136_CR39","doi-asserted-by":"crossref","unstructured":"Pessoa NL, Bentes AA, de Carvalho AL, Silva TBD, Alves PA, Reis EVD, et al. Case report: hepatitis in a child infected with SARS-CoV-2 presenting toll-like receptor 7 Gln11Leu single nucleotide polymorphism. Virol J. 2021;18:1\u20135.","DOI":"10.1186\/s12985-021-01656-3"},{"key":"1136_CR40","doi-asserted-by":"crossref","unstructured":"Solanich X, Vargas-Parra G, van der Made CI, Simons A, Schuurs-Hoeijmakers J, Antoli A, et al. Genetic Screening for TLR7 variants in young and previously healthy men with severe COVID-19. Front Immunol. 2021;12:719115.","DOI":"10.3389\/fimmu.2021.719115"},{"key":"1136_CR41","unstructured":"Butler-Laporte G, Povysil G, Kosmicki J, Cirulli ET, Drivas T, Furini S, et al. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative. medRxiv. 2022. p. 2022.03.28.22273040."},{"key":"1136_CR42","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/35100529","volume":"1","author":"R Medzhitov","year":"2001","unstructured":"Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135\u201345.","journal-title":"Nat Rev Immunol"},{"key":"1136_CR43","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1126\/science.1093620","volume":"303","author":"F Heil","year":"2004","unstructured":"Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526\u20139.","journal-title":"Science"},{"key":"1136_CR44","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1126\/science.1093616","volume":"303","author":"SS Diebold","year":"2004","unstructured":"Diebold SS, Kaisho T, Hemmi H, Akira S, Sousa CRE. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529\u201331.","journal-title":"Science"},{"key":"1136_CR45","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.micinf.2020.04.009","volume":"22","author":"MA Moreno-Eutimio","year":"2020","unstructured":"Moreno-Eutimio MA, Lopez-Macias C, Pastelin-Palacios R. Bioinformatic analysis and identi fication of single -stranded RNA sequences recognized by TLR7\/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. Microbes Infect. 2020;22:226\u20139.","journal-title":"Microbes Infect"},{"key":"1136_CR46","unstructured":"Zhang Q, Bastard P, Liu ZY, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570."},{"key":"1136_CR47","doi-asserted-by":"crossref","unstructured":"Abolhassani H, Landegren N, Bastard P, Materna M, Modaresi M, Du LK, et al. Inherited IFNAR1 Deficiency in a child with both critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome. J Clin Immunol. 2022;42:471\u201383.","DOI":"10.1007\/s10875-022-01215-7"},{"key":"1136_CR48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10875-021-01166-5","volume":"42","author":"S Khanmohammadi","year":"2022","unstructured":"Khanmohammadi S, Rezaei N, Khazaei M, Shirkani A. A case of autosomal recessive interferon alpha\/beta receptor Alpha Chain (IFNAR1) deficiency with severe COVID-19. J Clin Immunol. 2022;42:19\u201324.","journal-title":"J Clin Immunol"},{"key":"1136_CR49","doi-asserted-by":"crossref","unstructured":"Duncan CJA, Skouboe MK, Howarth S, Hollensen AK, Chen R, Borresen ML, et al. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. J Exp Med. 2022;219:e20212427.","DOI":"10.1084\/jem.20212427"},{"key":"1136_CR50","doi-asserted-by":"crossref","unstructured":"Schmidt A, Peters S, Knaus A, Sabir H, Hamsen F, Maj C, et al. TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19. NPJ Genom Med. 2021;6:55.","DOI":"10.1038\/s41525-021-00220-w"},{"key":"1136_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jgar.2021.06.005","volume":"26","author":"SP Smieszek","year":"2021","unstructured":"Smieszek SP, Polymeropoulos VM, Xiao C, Polymeropoulos CM, Polymeropoulos MH. Loss-of-function mutations in IFNAR2 in COVID-19 severe infection susceptibility. J Glob Antimicrob Resist. 2021;26:239\u201340.","journal-title":"J Glob Antimicrob Resist"},{"key":"1136_CR52","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.ajhg.2021.05.017","volume":"108","author":"JA Kosmicki","year":"2021","unstructured":"Kosmicki JA, Horowitz JE, Banerjee N, Lanche R, Marcketta A, Maxwell E, et al. Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. Am J Hum Genet. 2021;108:1350\u20135.","journal-title":"Am J Hum Genet"},{"key":"1136_CR53","doi-asserted-by":"crossref","unstructured":"Povysil G, Butler-Laporte G, Shang N, Wang C, Khan A, Alaamery M, et al. Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. J Clin Invest. 2021;131. Available from: https:\/\/www.jci.org\/articles\/view\/147834.","DOI":"10.1172\/JCI152475"},{"key":"1136_CR54","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","volume":"147","author":"I Meyts","year":"2021","unstructured":"Meyts I, Bucciol G, Quinti I, Neven B, Fischer A, Seoane E, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. J Allergy Clin Immun 2021;147:520\u201331.","journal-title":"J Allergy Clin Immun"},{"key":"1136_CR55","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jaci.2020.12.620","volume":"147","author":"AM Shields","year":"2021","unstructured":"Shields AM, Burns SO, Savic S, Richter AG. UK PIN COVID-19 Consortium. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. J Allergy Clin Immun 2021;147:870.","journal-title":"J Allergy Clin Immun"},{"key":"1136_CR56","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s10875-021-01066-8","volume":"41","author":"ES Goudouris","year":"2021","unstructured":"Goudouris ES, Pinto-Mariz F, Mendonca LO, Aranda CS, Guimaraes RR, Kokron C, et al. Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study. J Clin Immunol. 2021;41:1479\u201389.","journal-title":"J Clin Immunol"},{"key":"1136_CR57","doi-asserted-by":"crossref","unstructured":"Deya-Martinez A, Garcia-Garcia A, Gonzalez-Navarro EA, Yiyi L, Vlagea A, Jordan I, et al. COVID-19 in children and young adults with moderate\/severe inborn errors of immunity in a high burden area in pre-vaccine era. Clin Immunol. 2021;230:108821.","DOI":"10.1016\/j.clim.2021.108821"},{"key":"1136_CR58","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2020.09.016","volume":"183","author":"CR Consiglio","year":"2020","unstructured":"Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 2020;183:968\u201381.e7.","journal-title":"Cell"},{"key":"1136_CR59","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJMoa2021680","volume":"383","author":"LR Feldstein","year":"2020","unstructured":"Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl J Med. 2020;383:334\u201346.","journal-title":"N. Engl J Med"},{"key":"1136_CR60","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jaci.2021.06.024","volume":"148","author":"JE Chou","year":"2021","unstructured":"Chou JE, Platt CD, Habiballah S, Nguyen AA, Elkins M, Weeks S, et al. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). J Allergy Clin Immun. 2021;148:732\u2212+.","journal-title":"J Allergy Clin Immun"},{"key":"1136_CR61","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jaci.2020.07.033","volume":"146","author":"PY Lee","year":"2020","unstructured":"Lee PY, Platt CD, Weeks S, Grace RF, Maher G, Gauthier K, et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immun 2020;146:1194\u2212+.","journal-title":"J Allergy Clin Immun"},{"key":"1136_CR62","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41586-022-04447-0","volume":"603","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Bastard P, Cobat A, Casanova JL. COVID human genetic effort. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature 2022;603:587\u201398.","journal-title":"Nature"},{"key":"1136_CR63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1126\/science.abd4585","volume":"370","author":"P Bastard","year":"2020","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020;370:423.","journal-title":"Science"},{"key":"1136_CR64","doi-asserted-by":"publisher","first-page":"eabh2624","DOI":"10.1126\/scitranslmed.abh2624","volume":"13","author":"MGP van der Wijst","year":"2021","unstructured":"van der Wijst MGP, Vazquez SE, Hartoularos GC, Bastard P, Grant T, Bueno R, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021;13:eabh2624.","journal-title":"Sci Transl Med"},{"key":"1136_CR65","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03631-y","volume":"595","author":"EY Wang","year":"2021","unstructured":"Wang EY, Mao T, Klein J, Dai Y, Huck JD, Jaycox JR, et al. Diverse functional autoantibodies in patients with COVID-19. Nature 2021;595:283\u20138.","journal-title":"Nature"},{"key":"1136_CR66","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s10875-021-01036-0","volume":"41","author":"J Troya","year":"2021","unstructured":"Troya J, Bastard P, Planas-Serra L, Ryan P, Ruiz M, de Carranza M, et al. Neutralizing autoantibodies to Type I IFNs in >10% of patients with severe COVID-19 Pneumonia hospitalized in Madrid, Spain. J Clin Immunol. 2021;41:914\u201322.","journal-title":"J Clin Immunol"},{"key":"1136_CR67","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s00134-021-06392-4","volume":"47","author":"R Koning","year":"2021","unstructured":"Koning R, Bastard P, Casanova JL, Brouwer MC, van de Beek D. with the Amsterdam UMCCBI. autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 2021;47:704\u20136.","journal-title":"Intensive Care Med"},{"key":"1136_CR68","doi-asserted-by":"crossref","unstructured":"Bastard P, Orlova E, Sozaeva L, Levy R, James A, Schmitt MM, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218:e20210554.","DOI":"10.1084\/jem.20210554"},{"key":"1136_CR69","doi-asserted-by":"publisher","first-page":"100084","DOI":"10.1016\/j.xhgg.2021.100084","volume":"3","author":"A Bolze","year":"2022","unstructured":"Bolze A, Neveux I, Schiabor Barrett KM, White S, Isaksson M, Dabe S, et al. HLA-A\u221703:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination. Hum Genet Genomics Adv. 2022;3:100084.","journal-title":"Hum Genet Genomics Adv"},{"key":"1136_CR70","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41590-021-01030-z","volume":"23","author":"E Andreakos","year":"2022","unstructured":"Andreakos E, Abel L, Vinh DC, Kaja E, Drolet BA, Zhang Q, et al. A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. Nat Immunol. 2022;23:159\u201364.","journal-title":"Nat Immunol"},{"key":"1136_CR71","doi-asserted-by":"crossref","unstructured":"Brodin P, Casari G, Townsend L, O\u2019Farrelly C, Tancevski I, L\u00f6ffler-Ragg J, et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. 2022;28:879\u201382.","DOI":"10.1038\/s41591-022-01766-7"},{"key":"1136_CR72","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41591-021-01371-0","volume":"27","author":"SM Zekavat","year":"2021","unstructured":"Zekavat SM, Lin SH, Bick AG, Liu A, Paruchuri K, Wang C, et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med. 2021;27:1012\u201324.","journal-title":"Nat Med"},{"key":"1136_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26138-6","volume":"12","author":"KL Bolton","year":"2021","unstructured":"Bolton KL, Koh Y, Foote MB, Im H, Jee J, Sun CH, et al. Clonal hematopoiesis is associated with risk of severe Covid-19. Nat Commun. 2021;12:5975.","journal-title":"Nat Commun"},{"key":"1136_CR74","doi-asserted-by":"crossref","unstructured":"Kessler MD, Damask A, O\u2019Keeffe S, Meter MV, Banerjee N, Semrau S, et al. Exome sequencing of 628,388 individuals identifies common and rare variant associations with clonal hematopoiesis phenotypes. medRxiv. 2022. p. 2021.12.29.21268342.","DOI":"10.1101\/2021.12.29.21268342"},{"key":"1136_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86859-y","volume":"11","author":"I Alavi Darazam","year":"2021","unstructured":"Alavi Darazam I, Shokouhi S, Pourhoseingholi MA, Naghibi Irvani SS, Mokhtari M, Shabani M, et al. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. Sci Rep. 2021;11:8059.","journal-title":"Sci Rep"},{"key":"1136_CR76","unstructured":"Fu W, Liu Y, Xia L, Li M, Song Z, Hu H, et al. A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN-\u03ba plus TFF2 in patients with moderate COVID-19. eClinicalMedicine. 202025. Available from: https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(20)30222-4\/fulltext."},{"key":"1136_CR77","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC, Ramanan AV, Bono S, de, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respiratory Med. 2021;9:1407\u201318.","journal-title":"Lancet Respiratory Med"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01136-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01136-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01136-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T03:23:21Z","timestamp":1727493801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-022-01136-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1038\/s41431-022-01136-4","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}